Raymond James Maintains Strong Buy on CymaBay Therapeutics, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $17 to $33.
September 07, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James maintains a Strong Buy rating on CymaBay Therapeutics and raises the price target from $17 to $33.
The news is directly related to CymaBay Therapeutics. The Strong Buy rating maintained by Raymond James and the increase in price target from $17 to $33 indicates a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100